Our Mission
Our mission is simple yet unrelenting: to extend human life for all. Every person deserves the chance to live healthy, free from the limits of disease, and to fulfill their purpose surrounded by those they love.
​
Today, millions suffering from sickle cell disease, leukemia, lymphoma, and other blood-borne cancers face treatments that harm what they aim to heal. NanoCure AI Company exists to change that.
​
We are building the world’s first patent pending, drugless, non-toxic system designed to detect and remove hazardous cells directly from the bloodstream in real time. Our platform targets circulating tumor cells, sickled red blood cells, and other diseased cells with unmatched precision using advanced imaging, AI, and nanotechnology.
​
We will not rest until every person in need has access to a NanoCure AI Pod: a future where life is protected, health is restored, and no one’s story ends too soon.
Innovative
We are pioneering a new class of intelligent, drug-free therapy that targets disease at its source. Through our patent pending platform, NanoCure AI combines advanced imaging, artificial intelligence, and precision nanotechnology to detect, isolate, and eliminate harmful cells in real time, transforming how hematologic and cancer treatments are delivered.
Advanced
Advancing real-time, AI-guided solutions for CTCs, hematologic cancers & diseases . Our platform identifies and removes hazardous blood cells through intelligent imaging and precision nanotechnology, offering a safe, drug-free alternative to traditional therapies.
Tailored
Designed for personalized medicine, our adaptive platform tailors therapy to each patient’s blood profile and disease progression. Using continuous AI learning, it refines treatment precision in real time, ensuring safety, accuracy, and sustained results.
Comprehensive
Delivering end-to-end therapeutic coverage; from detection to restoration of healthy circulation. Our integrated system bridges diagnosis, therapy, and recovery, optimizing patient outcomes and redefining quality of care for hematologic diseases.
Medical Advisory Board
Our Medical Advisory Board brings together leaders in oncology, biomedical engineering, and clinical research who share a single mission: to heal without harm. These advisors provide strategic and scientific guidance that bridges discovery, validation, and patient application.
Their collective experience spans FDA and EMA approvals, global oncology trials, nanotechnology innovation, and translational medicine. Each member plays a vital role in shaping NanoCure AI’s clinical pathway, ensuring our therapeutic platform advances with scientific rigor, regulatory alignment, and unwavering commitment to patient safety.
_jfif.jpg)
Dr. Ashok Srivastava
MD, Ph.D., MBA
Our Medical & Technical Co-Founders
The NanoCure AI founding team brings experience across artificial intelligence, medical imaging, nanotechnology, precision engineering, and the study of hematologic malignancies. Collectively, our founders have contributed to more than 40 patents and 150 peer-reviewed publications, spanning FDA-cleared imaging systems, real-time AI inference pipelines, biocompatible nanomaterials, and translational research in blood-borne and solid-tumor diseases.
​
Our engineers and scientists bring together deep expertise in advanced optics, AI-driven analysis, and electromagnetic control, the essential building blocks of our intelligent therapeutic system. Collectively, they have designed and delivered high-speed microscopy platforms, closed-loop feedback architectures, and regulated medical-device technologies, embodying the intersection of innovation and clinical precision.
​
Together, we are creating a first-in-class, non-toxic therapeutic platform that redefines how the world detects and eliminates disease, at the cellular level and in real time.
The Vision Behind NanoCure AI Company
"​​I have always dreamed of creating real impact for my community, something tangible that improves lives in a lasting way. I never imagined that path would lead me to cancer therapy. I am a data-driven engineer by nature.
​
Every decision I make is rooted in research, experimentation, and evidence, not impulse. My journey toward NanoCure AI began after reading a research paper on nanoparticles and electromagnetic actuation. That single moment opened a world of possibility. When I connected those concepts with the emerging capabilities of modern microscopy and computer vision, I knew I was standing on the edge of something that could change the world.
​
For two years, I dedicated myself to designing this system, spending four to six hours each day after my full-time work in high-stress, niche networking roles at Amazon (Twitch and Kuiper). Those years were driven purely by passion and purpose.
​
NanoCure AI is more than an invention; it is my calling. I will not rest until this platform is complete. Our first therapeutic system will be the benchmark for success, and every medical device that follows will continue shaping the future of humanity, one discovery at a time."
Julius Lamar
Chief Executive Officer & Sole Inventor
Invest in the Future of Drug-Free Cellular Therapy
1. The Opportunity
Over 50 million people worldwide suffer from hematologic disorders or blood-borne cancers. Current therapies rely on drugs and chemicals that often harm healthy cells. NanoCure AI is developing the first non-toxic, AI-guided system designed to eliminate diseased cells directly from the bloodstream.
​
2. Why Now
Recent advances in AI-driven microscopy, nanomaterials, and micro-robotics have made real-time cellular therapy achievable. Our platform unites these technologies into a scalable medical device, ready for translational research and clinical validation.
​
3. How to Participate
We welcome early-stage investors, strategic partners, and foundations aligned with our mission to extend life and eradicate disease.
​
- Request Investor Deck or Schedule a Call at investors@nancureai.org